(PRESS RELEASE) What: CooperVision is underscoring its growing global leadership in myopia management with the release of Progress in Focus: The Global Impact of MiSight 1 day, a comprehensive report that captures the worldwide influence of its FDA-approved* MiSight 1 day contact lenses.
Drawing on cross-regional data and collaborations with leading researchers and eye care professionals (ECPs), the report provides the most comprehensive view to date of myopia’s global implications, and the measurable difference MiSight 1 day has made in children’s lives. It highlights progress in awareness, clinical adoption, and patient outcomes, reinforcing CooperVision’s leadership and commitment to combating the growing myopia epidemic.
View the report here: https://online.flippingbook.com/link/340522/
*Indications for use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
